Mirae Asset Global Investments Co., Ltd. Avidity Biosciences, Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $20 Billion
- Q2 2024
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 2,855 shares of RNA stock, worth $120,452. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,855
Previous 37,462
92.38%
Holding current value
$120,452
Previous $956,000
87.87%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding RNA
# of Institutions
206Shares Held
95.5MCall Options Held
171KPut Options Held
196K-
Price T Rowe Associates Inc Baltimore, MD10.9MShares$461 Million0.05% of portfolio
-
Rtw Investments, LP New York, NY8.81MShares$372 Million6.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$364 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY6.51MShares$274 Million3.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.94MShares$251 Million0.0% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $2.2B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...